COMPREHENSIVE HEALTHCARE SYS (CHS.CA) Fundamental Analysis & Valuation

TSX-V:CHSCA2046632071

Current stock price

0.79 CAD
+0.1 (+14.49%)
Last:

This CHS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CHS.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CHS has reported negative net income.
  • In the past year CHS has reported a negative cash flow from operations.
CHS.CA Yearly Net Income VS EBIT VS OCF VS FCFCHS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -1M -2M -3M -4M -5M

1.2 Ratios

  • CHS has a worse Return On Assets (-127.36%) than 66.67% of its industry peers.
Industry RankSector Rank
ROA -127.36%
ROE N/A
ROIC N/A
ROA(3y)-235.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHS.CA Yearly ROA, ROE, ROICCHS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • CHS has a better Gross Margin (60.93%) than 66.67% of its industry peers.
  • In the last couple of years the Gross Margin of CHS has grown nicely.
  • The Profit Margin and Operating Margin are not available for CHS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.64%
GM growth 5YN/A
CHS.CA Yearly Profit, Operating, Gross MarginsCHS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50 -100

0

2. CHS.CA Health Analysis

2.1 Basic Checks

  • CHS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CHS has about the same amount of shares outstanding.
  • The debt/assets ratio for CHS is higher compared to a year ago.
CHS.CA Yearly Shares OutstandingCHS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M
CHS.CA Yearly Total Debt VS Total AssetsCHS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

  • Based on the Altman-Z score of -38.34, we must say that CHS is in the distress zone and has some risk of bankruptcy.
  • CHS's Altman-Z score of -38.34 is on the low side compared to the rest of the industry. CHS is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -38.34
ROIC/WACCN/A
WACC8.71%
CHS.CA Yearly LT Debt VS Equity VS FCFCHS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 -2M -4M -6M

2.3 Liquidity

  • CHS has a Current Ratio of 0.06. This is a bad value and indicates that CHS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.06, CHS is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
  • CHS has a Quick Ratio of 0.06. This is a bad value and indicates that CHS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CHS has a Quick ratio of 0.06. This is amonst the worse of the industry: CHS underperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
CHS.CA Yearly Current Assets VS Current LiabilitesCHS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M

0

3. CHS.CA Growth Analysis

3.1 Past

  • CHS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.03%, which is quite impressive.
  • The Revenue has decreased by -1.73% in the past year.
  • The Revenue has been decreasing by -5.71% on average over the past years.
EPS 1Y (TTM)83.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114%
Revenue 1Y (TTM)-1.73%
Revenue growth 3Y-5.71%
Revenue growth 5YN/A
Sales Q2Q%14.27%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CHS.CA Yearly Revenue VS EstimatesCHS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 1M 2M 3M 4M

0

4. CHS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • CHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHS.CA Price Earnings VS Forward Price EarningsCHS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHS.CA Per share dataCHS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. CHS.CA Dividend Analysis

5.1 Amount

  • CHS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

CHS.CA Fundamentals: All Metrics, Ratios and Statistics

COMPREHENSIVE HEALTHCARE SYS

TSX-V:CHS (4/2/2026, 7:00:00 PM)

0.79

+0.1 (+14.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.81%
Ins Owner ChangeN/A
Market Cap19.71M
Revenue(TTM)4.16M
Net Income(TTM)-1.13M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.23
BVpS-0.3
TBVpS-0.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.36%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.93%
FCFM N/A
ROA(3y)-235.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.64%
GM growth 5YN/A
F-Score5
Asset Turnover4.69
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2741.67%
Cap/Sales 4.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -38.34
F-Score5
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.73%
Revenue growth 3Y-5.71%
Revenue growth 5YN/A
Sales Q2Q%14.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y70.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y102.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.84%
OCF growth 3YN/A
OCF growth 5YN/A

COMPREHENSIVE HEALTHCARE SYS / CHS.CA Fundamental Analysis FAQ

What is the fundamental rating for CHS stock?

ChartMill assigns a fundamental rating of 0 / 10 to CHS.CA.


What is the valuation status of COMPREHENSIVE HEALTHCARE SYS (CHS.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to COMPREHENSIVE HEALTHCARE SYS (CHS.CA). This can be considered as Overvalued.


How profitable is COMPREHENSIVE HEALTHCARE SYS (CHS.CA) stock?

COMPREHENSIVE HEALTHCARE SYS (CHS.CA) has a profitability rating of 1 / 10.


What is the financial health of COMPREHENSIVE HEALTHCARE SYS (CHS.CA) stock?

The financial health rating of COMPREHENSIVE HEALTHCARE SYS (CHS.CA) is 0 / 10.